Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

Market Cap	13.58B
Revenue (ttm)	948.40M
Net Income (ttm)	433.63M
Shares Out	79.63M
EPS (ttm)	5.34
PE Ratio	31.92
Forward PE	30.46
Dividend	5.12 (2.99%)
Ex-Dividend Date	Apr 30, 2025

Volume	221,914
Average Volume	251,169
Open	171.50
Previous Close	171.00
Day's Range	170.00 - 172.50
52-Week Range	143.50 - 215.00
Beta	0.42
RSI	57.68
Earnings Date	May 1, 2025

About TPEX:6712

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. It operates in two segments: Cell Preparation Business and Other Operating Business segments. The company’s products include umbilical cord mesenchymal stem cells (UMC01), a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine (ADCV01), a drug candidate in Phase II clinical trials for the ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6712

Financial Performance

In 2024, TPEX:6712's revenue was 933.81 million, an increase of 23.13% compared to the previous year's 758.39 million. Earnings were 367.25 million, a decrease of -31.91%.